The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p

Tissue Antigens

Volumn 47, Issue 2, 1996, Pages 117-121

  Lee, J E ^a   Loflin, P T ^a   Laud, P R ^a   Lu, M ^a   Reveille, J D ^a   Lawlor, D A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

HLA DQ antigen; Major histocompatibility complex; Melanoma; MHC class II; TAP allele

Indexed keywords

HLA DQ ANTIGEN; HLA DR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER SUSCEPTIBILITY; CENTROMERE; CHROMOSOME 6P; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; HISTOCOMPATIBILITY GENE; HLA SYSTEM; HUMAN; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0030046190     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02523.x     Document Type: Article

References (40)

1. Traversari C, van der Bruggen P, Luescher I et al. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolylic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992: 176: 1453-7.
2. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991: 254: 1643-7.
3. Brichard V, Van Pel A, Wölfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993: 178: 489-95.
4. Bakker A, Schreurs M, de Boer A et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994: 179: 1005-9.
5. Cox A, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994: 264: 716-9.
6. Kawakami Y, Eliyahu S, Delgado C et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994: 91: 6458-62.
7. Kawakami Y, Eliyahu S, Delgado C et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994: 91: 3515-9.
8. Coulie P, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994: 180: 35-42.
9. Powis S, Deverson E, Coadwell WJ et al. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 1992: 357: 211-5.
10. Heemels MT, Schumacher T, Wonigeit K, Ploegh H. Peptide translocation by variants of the transporter associated with antigen processing. Science 1993: 262: 2059-63.
11. Momburg F, Roelse J, Howard JC et al. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1991: 367: 648-51.
12. Lee JE, Reveille JD, Ross MI, Platsoucas CH. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994: 59: 510-513.
13. van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO. Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc Natl Acad Sci U S A 1992: 89: 11594-7.
14. Caillat-Zucman, Bertin E, Timsit J, Boitard C, Assan R, Bach J. Protection from insulin-dependent diabetes mellitus is linked to a peptide transporter gene. Eur J Immunol 1993: 23: 1784-8.
15. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics: 1993: 37: 266-73.
16. Reveille JD, Durban E, MacLeod-St. Clair MJ et al. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I - autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992: 90: 973-80.
17. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci U S A 1992: 89: 3932-6.
18. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 1993: 37: 373-80.
19. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA system, 1994. Hum Immunol 1994: 41: 1-20.
20. Jackson D, Capra JD: TAP1 alleles in insulin-dependent diabetes mellitus. A newly defined centromeric boundary of disease susceptibility. Proc Natl Acad Sci U S A 1993: 90: 11079-83.
21. Nakanishi K, Kobayashi T, Murase T, Kosaka K. Lack of association of the transporter associated with antigen processing with Japanese insulin-dependent diabetes mellitus. Metabolism 1994: 43: 1013-7.
22. Powis SH, Rosenberg WMC, Hall M et al. TAP1 and TAP2 polymorphism in coeliac disease. Immunogenetics 1993: 38: 345-50.
23. Kellar-Wood HF, Powis SH, Gray J, Compston DAS. MHC-encoded TAPI and TAP2 dimorphisms in multiple sclerosis. Tissue Antigens 1994: 43: 129-32.
24. Spurkland A, Knutsen I, Undlien D, Vartdal F. No association of multiple sclerosis to alleles at the TAP2 locus. Hum Immunol 1994: 39: 299-301.
25. Powis SH, Cooper MD, Trowsdale J, Zhu ZB, Volanakis JE. Major histocompatibility haplotypes associated with immunoglobulin-A deficiency and common variable immunodeficiency: analysis of the peptide transporter genes TAP1 and TAP2. Tissue Antigens 1994: 43: 261-5.
26. Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Natl Acad Sci U S A 1991: 88: 10094-8.
27. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991: 352: 723-5.
28. Heiland A, Borresen AL, Karen J, Ronningen KS, Thornsby E. HLA antigens and cervical cancer (letter). Nature 1992: 356: 23.
29. Uno H, Kawano K, Matsuoka H, Tsuda K. HLA and adult T cell leukaemia. HLA-linked genes controlling susceptibility to human T cell leukaemia virus type I. Clin Exp Immunol 1988: 71: 211-6.
30. Okada K, Boss JM, Prentice H et al. Gene organization of DC and DX subregions of the human major histocompatibility complex. Proc Natl Acad Sci U S A 1985: 82: 3410-4.
31. Tonnelle C, DeMars R, Long EO. DOB: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J 1985: 4: 2839-47.
32. Jonsson AK, Hyldig-Nielsen JJ, Servenius B et al. Class II genes of the human major histocompatibility complex. J Biol Chem 1987: 262: 8767-77.
33. Ando A, Kawai J, Maeda M, Tsuji K, Trowsdale J, Inoko H. Mapping and nucleotide sequence of a new HLA class II light chain gene, DQB3. Immunogenetics 1989: 30: 243-9.
34. Ragoussis J, Monaco A, Mockridge I, Kendall E, Campbell RD, Trowsdale J. Cloning of the HLA class II region in yeast artificial chromosomes. Proc Natl Acad Sci U S A 1991: 88: 3753-7.
35. Kozono H, Bronson SK, Taillon-Miller P, Moorti MK, Jamry I, Chaplin DD. Molecular linkage of the HLA-DR, HLA-DQ, and HLA-DO genes in yeast artificial chromosomes. Genomics 1991: 11: 577-86.
36. Nepom GT, Erlich H. MHC class II molecules and autoimmunity. Annu Rev Immunol 1991: 9: 493-525.
37. Campbell RD, Trowsdale T. Map of the human MHC. Immunol Today 1993: 14: 349-52.
38. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993: 177: 265-72.
39. Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994: 179: 335-40.
40. Wang Z, Cao Y, D'Urso C, Houghton A, Ferrone S. Molecular abnormalities in the expression of HLA class-I antigens by melanoma cells. Int J Cancer 1991: 6: 101-5.